Pharmalink is a Swedish specialty pharma company developing high-value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical development and marketing identify and progress products that address significant unmet medical needs.
With a successful history in pharmaceutical sales and marketing and highly experienced, dynamic management team, Pharmalink is currently focused on the development of valuable, de-risked projects.
Pharmalink has two late-stage clinical phase products under development, Nefecon® and Busulipo™, which are both expected to complete pivotal studies in 2015.
In addition to driving its existing products towards commercialisation, Pharmalink is actively seeking opportunities to acquire or in-licence product opportunities in niche and hospital care indications in oncology and inflammation.
Link to corporate leaflet.
Link to NEFIGAN Trial.